RBC Capital Adds 'Speculative Risk' Qualifier to Concordia (CXRX) Rating, PT Cut to $14
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
RBC Capital analyst Douglas Miehm added a Speculative Risk qualifier to his Outperform rating on Concordia Healthcare (NASDAQ: CXRX) and lowered his price target to $14.00 (from $25.00).
Miehm commented, "The NHS tabled a bill late last week to further control UK medical costs. While we have highlighted this risk for some time, we note that the impact on AMCo remains relatively unknown, so we have adopted a cautious stance and reduced 2017E revenues by ~$32MM and Adj. EBITDA by ~$26MM. While CXRX appears inexpensive, we have assigned a Speculative Risk qualifier given likely volatility. We also lower our price target to $14 from $25."
Shares of Concordia Healthcare closed at $5.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Cuts Price Target on Pentair (PNR) to $66 Following 3Q Report
- Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
- Akamai (AKAM) PT Raised to $65 at Stifel
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!